Research programme: gene therapies - Genetix Pharmaceuticals

Drug Profile

Research programme: gene therapies - Genetix Pharmaceuticals

Alternative Names: LentiDL™; LentiFVIII™; LentiNeur™; LentiRA™; LentiVue™

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Genetix Pharmaceuticals
  • Developer bluebird bio; Brigham and Womens Hospital; Columbia University; Harvard University; INSERM
  • Class Gene therapies
  • Mechanism of Action Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • No development reported Haemophilia A; Hypercholesterolaemia; Macular degeneration; Neurological disorders; Rheumatoid arthritis

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Rheumatoid-arthritis in USA (Parenteral)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Macular-degeneration in USA (Ophthalmic)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Neurological-disorders in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top